Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Operating Expenses: 2020-2024

Historic Operating Expenses for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $156.7 million.

  • Monte Rosa Therapeutics' Operating Expenses rose 27.98% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $173.0 million, marking a year-over-year increase of 20.20%. This contributed to the annual value of $156.7 million for FY2024, which is 9.37% up from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Operating Expenses of $156.7 million as of FY2024, which was up 9.37% from $143.3 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Operating Expenses high stood at $156.7 million for FY2024, and its period low was $28.0 million during FY2020.
  • For the 3-year period, Monte Rosa Therapeutics' Operating Expenses averaged around $137.5 million, with its median value being $143.3 million (2023).
  • Data for Monte Rosa Therapeutics' Operating Expenses shows a peak YoY spiked of 160.20% (in 2021) over the last 5 years.
  • Over the past 5 years, Monte Rosa Therapeutics' Operating Expenses (Yearly) stood at $28.0 million in 2020, then skyrocketed by 160.20% to $72.9 million in 2021, then surged by 54.20% to $112.4 million in 2022, then climbed by 27.52% to $143.3 million in 2023, then increased by 9.37% to $156.7 million in 2024.